IRCT2015112025146N1已完成未知
comparison of the effect of Fingolimode and Betaferon (high dose) in decreasing the symptoms and relapse rates of MS patients whose treatment with Betaferon (low dose) was failed.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •The most important one is MS patients who had treatment failure (relapsing rate more than one) under Betaferon ( low dose) ; patient acceptance; non immunosuppressive patient.
- •Exclusion criteria: noncooperative patient; death
排除标准
- 未提供
研究者
相似试验
尚未招募
不适用
Study of absorption and elimination rate of Fingolimod 0.5-mg capsule in comparison with Fingolimod brand Capsule (Gilenya®).Bioequivalence study.IRCT20200407046981N26Zahravi pharmaceutical company24
招募中
Unknown
Bioequivalence study of Fingolimod 0.5 mg capsuleIRCT20200105046010N92Abidi Company24
招募中
2 期
An efficacy and safety comparison study of Fenofibrate and omega 3 in pediatric patients with Hypertriglyceridemia, A Randomized Clinical TrialHypertriglyceridemia.Pure hyperglyceridemia, Endogenous hyperglyceridemiaE78.1IRCT20220516054879N4Rasht University of Medical Sciences60
招募中
2 期
Effect of Fingolimod in Multiple SclerosisMultiple sclerosisMultiple Sclerosis.IRCT20180204038608N1Tabriz University of Medical Sciences30
招募中
Unknown
Bioequivalence study of Fingolimod capsule 0.5 mgIRCT20200623047902N34Alborz Zagros company24